Please tell us about your clinical experience. How many patients with NF1-Associated Plexiform Neurofibromas do you see on a yearly basis? What is the standard of care and what treatments are available?

How much of a need is there for novel treatments of plexiform neurofibromas? How often does the disease cause severe disfigurement, pain, and functional impairment?

Can you walk us through the reasoning behind MEK inhibitors as a validated class of treatment for NF1-PN? And can you tell us more about the four approved MEK inhibitors, trametinib, binimetinib, selumetinib, and cobimetinib and how they might compare to mirdametinib?

How important is the drug's ability to be taken without regard to food, and the expected availability of a pediatric formulation?

Mirdametinib is to be administered in a 3-week on, 1-week off dosing schedule, at a dose of 2 mg/m2 twice daily (maximum dose of 4 mg twice daily). How does this schedule and dosing compare to standard of care? Would it help increase patient compliance? Has that been an issue?

Could you please discuss the interim data, where:-50% of patients had achieved an objective response as assessed by blinded independent central review- 80% remained on study, and median time on treatment was 13 cycles (12 months). -majority of treatment-related adverse events were Grade 1 or 2; -one Grade 3 TRAE and no Grade 4 or 5 adverse events were reported in these 20 patients.

How inclined would you be to prescribe mirdametinib for your patients, judging by the data?